CMF
CLPT icon

Counterpoint Mutual Funds’s ClearPoint Neuro CLPT Stock Holding History

Counterpoint Mutual Funds’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23,571
Closed -$514K – 383
2025
Q3 		$514K Buy
+23,571
New +$278K 0.04% 100

Other funds holding CLPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
FCM
FirstWave Capital Management Miami, Florida $94.1M AUM
LG
Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Counterpoint Mutual Funds's CLPT Position: Q4 2025 in Review

Counterpoint Mutual Funds sold out of ClearPoint Neuro (CLPT) in Q4 2025, closing a stake of 23,571 shares — an estimated $514K sold.

Counterpoint Mutual Funds first reported a position in CLPT in Q3 2025 and held it in 1 quarter. The position peaked at $514K in Q3 2025. 118 funds tracked by Wall St. Rank hold CLPT as of Q4 2025.

  • Counterpoint Mutual Funds reported no remaining ClearPoint Neuro position as of Q4 2025 after selling out during the quarter.
  • Counterpoint Mutual Funds sold 23,571 ClearPoint Neuro shares in Q4 2025, an estimated $514K.
  • Counterpoint Mutual Funds first reported a position in ClearPoint Neuro in Q3 2025 and held it in 1 quarter.
  • Counterpoint Mutual Funds's ClearPoint Neuro position peaked at $514K in Q3 2025.
  • 118 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q4 2025.

Based on Counterpoint Mutual Funds's 13F filing for Q4 2025, filed 12 Feb 2026.